



Who We Are

At Trebe Biotech, we harness the untapped potential of insects to revolutionize the biotech industry. Our innovative platform uses insect larvae—not traditional bioreactors—to produce high-value bioproducts such as recombinant proteins and vaccines. By reprogramming the natural protein expression capabilities of insects, we offer a simple, smart, and scalable solution to meet the global demands of animal health and beyond.

Why Our Platform

We surpass existing technologies

Capital costs

Minimal investment in equipment compared to traditional bioreactors.

Operating costs

Simplified operations with automated inoculation and larva incubation as single-use bioreactors.

Yield and efficiency

High yields in an efficient eukaryotic system with the shortest production time in the industry, achieving mammalian-like characteristics.

Downstream processing

Simple and adapted to produce high-activity products, efficiently covering a range from baculovirus vaccines to recombinant proteins, all in a single step.

Scale-up Considerations

Solves scalability of the upstream process without specific investments and in no time.

Sustainability

Harnessing lepidopteran larvae, our platform sustainably produces pharmaceuticals, cutting energy use and waste through natural processes, setting a new eco-friendly biotech standard.

Pipeline

Diagnostic Antigen

- Spike for SARS-CoV-2 antigen used for an ANMAT approved serological kit.
- Dengue Antigen for serological diagnosis of 4 serotypes. External validation and in use by private companies.

Immunogens for antivenoms


- Sphingomyelinase D for *Loxosceles laeta* antivenom production being registered by the public reference body, ANLIS, for use in the public healthcare network. Additionally, BIOL Laboratory is poised to register it for export to the regional market.

Veterinary treatments

- Feline and canine interferons. In vitro validation of their antiviral and antitumor activity has been confirmed by the Nanobiotec Institute and the Ángel H. Roffo Institute of Oncology.
- Two bovine FSH prototypes under validation at ICIVET.

Veterinary vaccines

- Baculoviral particle based platform.
- Avian Influenza H5N1 candidate under validation as proof-of-concept.



Contact Us



+549-1136549458



ignacio.smith@trebebiotech.com